China-Developed Artificial Skin Ready For Production
This article was originally published in PharmAsia News
Executive Summary
Shaanxi Province has broken ground for its Research and Development Center for Tissue Engineering in Xi'an High-Tech Industrial Development Zone. With a total investment of RMB 120 million, the project is expected to realize a yearly revenue of RMB 1 billion when it goes into operation. The facility will have an annual output of 3 million cm2 of artificial skin, 30,000 corneas and 10 million cm2 of selective acellular double-layer dermal matrix produced by tissue engineering. Developed by Fourth Military Medical University, it is the nation's only such technology with independent intellectual property rights that can successfully produce engineered tissue products. The project makes China the second country to commercialize tissue engineering technology after the U.S. (Click here for more - Chinese Language)
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.